biologic

Xeomin

incobotulinumtoxinA

Loss of exclusivityJuly 2022projected — 12-year biologic exclusivity estimate
CompanyMerz Pharmaceuticals GmbH c/o Merz Pharmaceuticals LLC

Drug detail

Brand nameXeomin
Active ingredientincobotulinumtoxinA
Strength50UNITS
Dosage formFor Injection
RouteIntramuscular, Intraglandular
ModalityBiologic
FDA approvalJuly 2010
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Xeomin patent cliff — loss of exclusivity July 2022 | CliffBio